Real-time quartz crystal microbalance cytosensor based on a signal recovery strategy for in-situ and continuous monitoring of multiple cell membrane glycoproteins.
A real-time quartz crystal microbalance (QCM) cytosensor based on a signal recovery strategy was first developed for in-situ and continuous monitoring of multiple cell membrane glycoproteins. In this work, gold nanoparticles (AuNPs) were linked with ligands to fabricate ligand-functionalized mass nanoprobes with signal amplification for increasing monitoring sensitivity. The mass nanoprobes bound to cell surface could be eluted with glycine-hydrochloric acid buffer, which led to a quick recovery of resonance frequency. Using the strategy, folate receptors (FR), CD44 molecule and epidermal growth factor receptor (EGFR) on cell membrane as the models were monitored continuously. The quantification result of MDA-MB-231 cells showed a range of linearity of 3.0 × 104 to 1.0 × 106 cells and a detection limit of 5.0 × 103 cells. Furthermore, the multianalyte cytosensor exhibited three sensitive and recoverable frequency shifts during continuous monitoring for in-situ and continuous evaluation of the expression levels of FR, CD44 and EGFR on cell membrane, which exhibited that the average numbers of molecules of FR, CD44 and EGFR per MDA-MB-231 cell were 0.5 × 106, 0.2 × 106 and 1.4 × 105 with the relative standard deviation of 4.8%, 4.5% and 5.1%, respectively. Compared with monolithic multichannel QCM, the multianalyte cytosensor based on a single microbalance could not only exclude acoustic interference but also reduce instrumental cost. This work provided a simple and efficient QCM cytosensor for in-situ and continuous monitoring of multiple cell membrane glycoproteins that offered a new avenue for early diagnosis of cancer.